Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.45 |
| ▸ | SETD2 | Q9BYW2 | 11/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606689 | 1.00 | SMYD3 (0.45) | SMYD3SETD2HRH4NSD2ROCK2 | |
| SCHEMBL25531879 | 0.83 | SMYD3 (0.43) | SMYD3SETD2HRH4NSD2ROCK2 | |
| SCHEMBL3604285 | 0.82 | SMYD3 (0.67) | SMYD3SETD2HRH4NSD2SYK | |
| SCHEMBL3604282 | 0.82 | SMYD3 (0.67) | SMYD3SETD2HRH4NSD2SYK | |
| SCHEMBL3610017 | 0.82 | SMYD3 (0.67) | SMYD3SETD2HRH4NSD2SYK | |
| SCHEMBL3611824 | 0.80 | SMYD3 (0.47) | SMYD3SETD2NSD2CYP2C8DRD2 | |
| SCHEMBL3611827 | 0.80 | SMYD3 (0.47) | SMYD3SETD2NSD2CYP2C8DRD2 | |
| SCHEMBL3611744 | 0.80 | HRH4 (0.56) | SMYD3SETD2HRH4NSD2SYK | |
| SCHEMBL3611741 | 0.80 | HRH4 (0.56) | SMYD3SETD2HRH4NSD2SYK | |
| SCHEMBL3608629 | 0.78 | MLLT1 (0.69) | SMYD3HRH4ROCK2MLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SMYD3 811/4885SETD2 2175/4885HRH4 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.